# A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

> **NCT05933070** · PHASE1 · TERMINATED · sponsor: **Inmune Bio, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Cancer
- MDS-EB
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- AML

## Interventions

- **BIOLOGICAL:** INKmune

## Key facts

- **NCT ID:** NCT05933070
- **Lead sponsor:** Inmune Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-15
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-04-26
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow/low Enrollment
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933070, "A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05933070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*